P/B
3,1
Cellectis
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
$126.8M
Market Cap • 10/9/2026
2000
(26 years)
Founded
2015
(11 years ago)
IPO
NASDAQ
Listing Exchange
France
Country
Valuation
P/S
2
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,4
EPS
—
Market Cap
Market Cap
126,8M
EV
64,3M
EV/Revenue
1
EV/EBITDA
-1,7
EV/EBIT
-1,1
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0%
Total Yield
0%
Payout
0%
Retained Earnings
-303,9M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
3,4%
Capex/D&A
11,4%
Capex/OCF
-5,2%
SBC/OCF
—
% PPE
20,2%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-1,4%
CAGR Op. Income 5Y
-14,1%
CAGR Net Income 5Y
-14,8%
CAGR EPS 5Y
-25,4%
CAGR OCF 5Y
-18%
Leverage
N.D./EBITDA
1,6
Debt/Equity
0%
Current Ratio
1,4
Quick Ratio
1,3
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!